Piramal Pharma vs Syngene International: Share Price, Comparison and Key Differences
- August 11, 2026
- Posted by: Neeraj Pandey
- Category: News
Piramal Pharma MCap Rs 27,878 Cr, loss-making (EPS -2.36, ROE -3.58%). Syngene International MCap Rs 16,286 Cr, PE 73.76x, ROE 7.76%.
Piramal Pharma vs Syngene International is a comparison CDMO (Contract Development and Manufacturing Organisation) investors look up when evaluating two listed Indian companies serving global pharmaceutical companies. Piramal Pharma is a Mumbai-based CDMO and complex hospital generics company, demerged from Piramal Enterprises in 2022, providing CDMO services to global pharma, selling inhaled anaesthesia and critical care products in hospitals globally. Syngene International, a Bengaluru-based CRO and CDMO, is a Biocon group company providing integrated drug discovery, development and manufacturing services to global pharmaceutical and biotech companies.
This Piramal Pharma vs Syngene International article covers reach and market position, key products, latest declared results and stock valuation. The Piramal Pharma vs Syngene International data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.
Piramal Pharma vs Syngene International: Reach and Market Position
On the Piramal Pharma side of the Piramal Pharma vs Syngene International comparison, Piramal Pharma provides CDMO manufacturing from facilities in North America, Europe and India, and sells critical care hospital generics globally. Market capitalisation is Rs 27,878 Cr.
Click Here – Get Free Investment Predictions
On the Syngene International side of the Piramal Pharma vs Syngene International comparison, Syngene International provides drug discovery (chemistry, biology), development and manufacturing services from Bengaluru, Hyderabad and Mangaluru. Market capitalisation is Rs 16,286 Cr.
Piramal Pharma vs Syngene International: Key Products and Business Mix
In the Piramal Pharma vs Syngene International product comparison, Piramal Pharma offers: Piramal Pharma earns from CDMO contract manufacturing, critical care hospital products (inhaled anaesthetics, ophthalmology) and complex generics. EPS is -Rs 2.36 (loss-making). ROE is -3.58 percent. Piramal Pharma is currently loss-making as it invests in CDMO facility expansion.
For Syngene International in this Piramal Pharma vs Syngene International breakdown: Syngene earns from integrated drug research services, biological CDMO manufacturing and dedicated research scientist teams for global pharma partners. EPS is Rs 5.47. PE is 73.76x, ROE 7.76 percent, D/E 0.09.
Piramal Pharma vs Syngene International: Latest Results
The Piramal Pharma vs Syngene International results for Piramal Pharma: Piramal Pharma has a market cap of Rs 27,878 Cr and is loss-making with EPS of -Rs 2.36 and ROE of -3.58 percent. Investors considering Piramal Pharma should note its loss-making status before any investment decision. Piramal Pharma is 1.7 times larger than Syngene.
The Piramal Pharma vs Syngene International results for Syngene International: Syngene International has a market cap of Rs 16,286 Cr and PE of 73.76x. ROE is 7.76 percent. Syngene is profitable with a growing CDMO and CRO platform backed by Biocon.
Compare Piramal Pharma and Syngene International Fundamentals on the Univest Screener
Piramal Pharma vs Syngene International: Stock and Valuation
The Piramal Pharma vs Syngene International stock comparison uses the latest available market data from Groww. Investors tracking Piramal Pharma vs Syngene International should verify current prices on NSE or BSE before trading.
Piramal Pharma vs Syngene at current valuations: Piramal Pharma is loss-making at Rs 27,878 Cr market cap. Syngene trades at Rs 16,286 Cr market cap, PE 73.76x, ROE 7.76 percent. Piramal Pharma has greater scale but is loss-making. Syngene is profitable with a research-to-manufacturing CDMO platform.
Piramal Pharma vs Syngene International: Quick Comparison Table
The Piramal Pharma vs Syngene International comparison table below summarises the key metrics covered in this article side by side.
| Parameter | Piramal Pharma | Syngene International |
|---|---|---|
| Sector | CDMO + hospital generics + critical care (North America, Europe) | Integrated CRO + CDMO: drug discovery to manufacturing (Biocon group) |
| Market Cap | Rs 27,878 Cr | Rs 16,286 Cr |
| P/E Ratio | N/A (loss-making) | 73.76x |
| ROE | -3.58% (losses) | 7.76% |
| Profitability | Loss-making | Profitable |
| Debt to Equity | 0.70 | 0.09 |
| Client Base | Global pharma (CDMO) + hospitals (critical care) | Global pharma and biotech (dedicated research + CDMO) |
Conclusion
The Piramal Pharma vs Syngene International comparison above covers the key data points on reach, products, results and valuation. Piramal Pharma vs Syngene International covers two Indian CDMO companies serving global pharma clients. Piramal Pharma is currently loss-making from facility investment and restructuring costs following its demerger. Syngene is profitable with a fully integrated drug research and manufacturing model. Piramal Pharma vs Syngene investors should review Piramal’s path to profitability, CDMO order wins and Syngene’s clinical trial revenue and biologics CDMO growth. Consult a SEBI-registered advisor before investing in either stock.
Download the Univest iOS App or Univest Android App to track Piramal Pharma and Syngene International live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What does Piramal Pharma do?
Ans. Piramal Pharma provides CDMO (Contract Development and Manufacturing) services to global pharmaceutical companies, manufactures inhaled anaesthetics and critical care hospital products (Ketamine, Sevoflurane), and sells complex generics internationally.
What does Syngene International do?
Ans. Syngene provides integrated drug research and manufacturing services – from early-stage drug discovery chemistry and biology through clinical development manufacturing – for global pharma and biotech clients on a contract basis.
Why is Piramal Pharma loss-making?
Ans. Piramal Pharma’s losses reflect high depreciation and amortisation from its CDMO facility investments, restructuring costs following its demerger from Piramal Enterprises and working capital investments in expanding its global CDMO capacity.
What is a CDMO?
Ans. A CDMO (Contract Development and Manufacturing Organisation) develops drug formulations and manufactures finished pharmaceutical products on behalf of pharmaceutical companies that prefer to outsource production rather than build their own plants.
Is Syngene a Biocon subsidiary?
Ans. Yes. Syngene International is a Biocon Group company – Kiran Mazumdar-Shaw’s Biocon holds a majority stake. Syngene was listed separately in 2015.
Are Piramal Pharma and Syngene in Nifty 50?
Ans. Neither is in Nifty 50. Both are tracked in broader indices.
Which is larger, Piramal Pharma or Syngene?
Ans. Piramal Pharma at Rs 27,878 Cr is approximately 1.7 times larger than Syngene International at Rs 16,286 Cr.
